NCT07371338 is a Phase 1 clinical trial of IPS101A in Parkinson Disease, sponsored by Innopeutics Corporation.

Who is sponsoring NCT07371338?

NCT07371338 is sponsored by Innopeutics Corporation.

What drugs are being tested in NCT07371338?

Interventions in NCT07371338: IPS101A.

What condition does NCT07371338 study?

NCT07371338 studies Parkinson Disease, Parkinson's Disease.

Is NCT07371338 still recruiting?

NCT07371338 is currently recruiting now. Last updated 25 March 2026.

Last reviewed 2026-03-25 · How we verify

NCT07371338

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients

Recruiting now Phase 1 Last updated 25 March 2026

What this trial tests

Phase 1 trial testing IPS101A in Parkinson Disease in 6 participants. Currently enrolling.

Timeline

30 May 2026

Primary endpoint
31 October 2027

31 December 2027

Quick facts

Lead sponsor	Innopeutics Corporation
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	6
Start date	30 May 2026
Primary completion	31 October 2027
Estimated completion	31 December 2027
Sites	1 location across South Korea

Drugs / interventions tested

IPS101A — full drug profile →

Conditions studied

Parkinson Disease — all drugs for Parkinson Disease →
Parkinson's Disease — all drugs for Parkinson's Disease →

Sponsor

Innopeutics Corporation — full company profile →

Who can join

Adults 50 to 80, any sex, with Parkinson Disease or Parkinson's Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the dose-related safety and tolerability of IPS101A, an adeno-associated virus (AAV) gene therapy, in patients with Parkinson's disease who exhibit severe functional impairment corresponding to Hoehn \& Yahr stages 4-5 and whose symptoms are not adequately controlled despite all available monotherapy and combination therapy options. In addition, the study aims to assess the maximum tolerated dose (MTD) of IPS101A, as well as its preliminary efficacy and pharmacokinetic (PK) characteristics.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Parkinson Disease

Currently open trials in the same condition.

NCT07399496 — Accelerated TMS for Apathy in PD · NA · recruiting
NCT07442370 — The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients · NA · recruiting
NCT06848205 — Percept Transitions in FOG and PD · NA · recruiting
NCT07432958 — A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (P · Phase 2 · recruiting
NCT06885541 — Detection of Internal Tremors by Oscillometry in Parkinson's Patient · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07371338 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Innopeutics Corporation
Last refreshed: 25 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07371338.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing